Product Overview

Description

The antibody was found to effectively inhibit the interaction between PCSK9 and LDL receptor, as well as to inhibit LSK receptor degradation via PCSK9. In vivo, the antibody was found to inhibit PCSK9, thereby increasing the level of LDL receptor present. In addition, the antibody neutralized the in vivo cholesterol elevation observed when exogenous PCSK9 was added.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

WB; Inhib; Block; In Vitro; In Vivo

Application Notes

BACE1

Relevant Diseases

Alzheimer's Disease; Stroke; Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;